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Abstract
Differentiation programs are aberrant in cancer cells allowing them to express differentiation markers in addition to their
tissue of origin. In the present study, we demonstrate the multi-lineage differentiation potential of breast cancer cell lines to
express multiple neuronal/glial lineage-specific markers as well as mammary epithelial and melanocytic-specific markers.
Multilineage expression was detected in luminal (MCF-7 and SKBR3) and basal (MDA-MB-231) types of human breast cancer
cell lines. We also observed comparable co-expression of these three cell lineage markers in MDA-MB-435 cells in vitro,i n
MDA-MB-435 primary tumors derived from parental and single cell clones and in lung metastases in vivo. Furthermore,
ectoderm multi-lineage transdifferentiation was also found in human melanoma (Ul-MeL) and glioblastoma cell lines (U87
and D54). These observations indicate that aberrant multi-lineage transdifferentiation or lineage infidelity may be a wide
spread phenomenon in cancer.
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Introduction
Cancer diagnosis of the tissue origin of metastatic lesions,
especially those from occult primary tumors, relies heavily on the
expression of cellular or tissue differentiation markers. Emerging
clinical and pre-clinical evidence show that the differentiation
programs are aberrant in cancer cells allowing them to express
differentiation markers beyond their tissue of origin [1–3]. These
observations have implications for both cancer research and
clinical management of cancer. However, this property has not
been thoroughly examined in human cancer cell lines that are
frequently used in cancer research.
A microarray analysis has indicated that the gene expression
pattern of the human MDA-MB-435 [4] resembles that of human
melanoma cell lines [5]. Since then, additional evidence has shown
the ability of MDA-MB-435cellstoexpressmelanocyticmarkers [6–
8]. However, upon induction with heregulin in vitro, MDA-MB-435
cells undergo sufficient mammary epithelial differentiation to
produce milk lipid droplets and to express b-casein mRNA [9].
Additionally, enhanced expression of NM23-H1 metastasis suppres-
sor gene leads to the formation of organized mammary acinus-like
sphere in 3D culture and the expression of sialomucin (epithelial
membraneantigen,EMA)[10].Arecentinvestigationconfirmedthe
ability of MDA-MB-435 cells to co-express markers of mammary
epithelium and melanocytes both in vitro and in vivo, and postulated
committing lineage infidelity as an underlying mechanism for the
observed dual lineage transdifferentiation [11]. Furthermore,
another recent study reported the robust expression of melanocyte-
related genes in a variety of breast cancer cell lines including MDA-
MB-435, and more importantly in freshly resected and histopath-
ologically confirmed human breast cancer specimens [12].
Here, we report the expression of multiple neuronal/glial
lineage-specific markers by MDA-MB-435 cultured cells in vitro
and in primary tumors and lung metastases in vivo in addition to
the reported expression of epithelial and melanocytic markers.
Furthermore, we observed the co-expression of three ectoderm cell
lineage markers in other luminal (MCF-7 and SKBR3) and basal
(MDA-MB-231) types of human breast cancer cell lines, as well as
in human melanoma and glioblastoma cancer cell lines generated
from tumors of ectoderm origin.
These observations indicate that while terminal differentiation
to the anticipated cellular type is compromised in the cancerous
state, aberrant multi-lineage transdifferentiation or lineage infi-
delity may be a wide spread in cancer phenomenon.
Materials and Methods
Cell culture
The MDA-MB-435s, MDA-MB-231, MCF-7 and MCF-10A
cell lines were obtained from ATCC (Manassa, VA). SKBR3 cells
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9712were gifts from Dr. Suzanne Conzen, University of Chicago. Ul-
Mel, U87, and D54 were from gifts from Dr. Ralph Weichsel-
baum, University of Chicago. All cells were cultured in DMEM
high glucose (Hyclon, Logan, Utah) supplemented with 10% FBS
and 1% penicillin/streptomycin. MDA-MB-435-GFP derivative
cell lines were generated from single cell cloning through initial
seeding of single cells in 96-well plates and subsequent expansion
of cell numbers. MDA-MB-435-GFP-L cell lines were generated
from resected lungs that harbor pleural metastases derived from
tail-vein injected MDA-MB-435-GFP cells and purified using
G418 for the selection of GFP expression.
PCR analysis of lineage markers expression
Total RNA was isolated using TRIZOL (Applied Biosystems
Inc. Foster City, CA) according to the manufacturer’s instructions,
followed by DNAse treatment (Promega, Madison, WI). cDNA
was reverse transcribed from 2 mg of total RNA using random
primer method (Applied Biosystems Inc.) according to the
manufacturer’s instructions. PCR amplification was performed
by incubation at 94uC for 1 min, followed by 32 cycles of 94uC for
30 s, 55uC for 30s, and 72uC for 25s. Amplified products were
separated and visualized on a 0.8% agarose gel. TBP was used as a
loading control.
The sequence for the primer sets used are as follows: Nestin (F:
aacagcgacggaggtctcta; R: ttctcttgtcccgcagactt), EMA (F: tcccag-
caccgactactacc; R: cagctgcccgtagttctttc), ESA (F: ggaagctgagtgcaa-
gaagg; R: gctgcacaacctcaatctca), TRY (F: tacggcgtaatcctggaaac; R:
attgtgcatgctgctttgag), Melan-A (F: gctcatcggctgttggtatt; R: ataag-
caggtggagcattgg), MITF (F: aactcatgcgtgagcagatg; R: tacttggtgg-
ggttttcgag), GFAP (F: acatcgagatcgccacctac; R: atctccacggtcttcac-
cac), TUBB3 (F: cagatgttcgatgccaagaa; R: gggatccactccacgaagta),
CK19 (F: tttgagacggaacaggctct; R: aatccacctccacactgacc), CK17
(F: gctgctacagctttggctct; R: tcacctccagctcagtgttg), and TBP (F:
tataatcccaagcggtttgc; R: cacagctccccaccatattc).
Immunofluorescence analysis of differentiation marker
expression in cultured cells
Five thousand unlabeled cells were plated in each chamber of 8-
well chamber slides (BD) and grown for 48 hours. Cells were fixed
with buffered formalin, permeabilized with 0.3% Triton X-100/
PBS, blocked with 10% goat serum (Vector S-1000)/PBS and
incubated with primary antibodies diluted in 2%BSA/16PBS for
1 hour: ESA (Anaspec, San Jose, CA) (1:100), melan-A (DAKO,
Carpinteria, CA) (1:100), Nestin (Abcam, Cambridge, MA) (1:250)
and GFAP (R &D, Minneapolis, MN) (1:100). Thereafter, cells
were incubated with Alexa 488-conjugated secondary antibodies
(Molecular Probes) for 30 min, followed by mounting with Prolong
Gold antifade reagent containing DAPI for nuclear counter-
staining. Slides were photographed with a Leica SP-2 confocal
microscope and images were processed with image J.
Immunohistochemistry (IHC) analysis of differentiation
marker expression in cultured cells, primary tumors, and
lung metastases
All animal studies were carried out according to protocols
approved by the IACUC Committee at the University of Chicago.
Six-week-old female athymic Ncr/nu/nu mice (NCI-Frederick), 18
to 20 g, were used. For orthotopic tumor implantation, 5610
6
cultured MDA-MB-435 cells suspended in 0.1 ml of PBS were
injected into the left inguinal mammary fat pad (m.f.p.). Tumors
were harvested upon reaching ,200 to 250 mm
3, fixed in
formalin and embedded in paraffin. To produce experimental
lung metastases, 1610
6 cultured MDA-MB-435-GFP cells,
suspended in 0.1 ml of PBS, were injected into the mouse tail
vein. Twelve weeks later, mouse lungs were dissected and fixed in
formalin and embedded in paraffin. The tumor and lung blocks
were cut into 5-mm paraffin sections. For IHC analysis, tissue
sections were deparafinized, rehydrated followed by antigen
retrieval and treated with 3% hydrogen peroxide to block
endogenous peroxidase activity. 1:100 dilution of cytokeratin
(DAKO, M3515), 1:100 dilution of melan-A (DAKO M7196),
1:100 GFAP (R & D System), and 1:500 dilution of Nestin
(Abcam, ab5968) were applied to the tissue slides and incubated
for one hour. Envision+anti-mouse system was used for antigen-
antibody detection. The slides were counter-stained with hema-
toxylin, air dried, and examined under light microscopy.
Results and Discussion
MDA-MB-435 cell lines derived from lung metastases
exhibit morphology of neuronal/glial differentiation
We generated an MDA-MB-435 cell line stably expressing
green fluorescent protein (GFP) [13] and have been using this
model routinely to produce experimental lung metastases for
conducting in vivo imaging experiments (data not shown). We
subsequently established MDA-MB-435-GFP sub-lines (MDA-
MB-435-GFP-L) from pleural metastases harvested 12 weeks after
tail vein injection of MDA-MB-435-GFP cells. In contrast to the
spindle-shaped parental MDA-MB-435-GFP cells (Figure 1A and
E), three representative MDA-MB-435-GFP-L cell lines displayed
Figure 1. MDA-MB-435 lung cell lines derived from lung
metastases display neuronal/glial differentiation morphology.
A and E, parental MDA-MB-435-GFP cells. B–D and F–H, three
representative MDA-MB-435-GFP-L cell lines exhibit morphological
features of well-differentiated neuron/glial cells.
doi:10.1371/journal.pone.0009712.g001
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the presence of polygonal soma (cell body), extended dendrites and
axons, and cell-cell communication at synapses (Figure 1 B–D
and F–H). Similar changes were also seen in non-GFP-labeled
parental MDA-MB-435 cells freshly obtained from ATCC and in
MDA-MB-435-GFP cell cultures set up at low seeding density
(data not shown). Exhibition of diverse neuronal morphological
features by MDA-MB-435 and MDA-MB-435-GFP-L cells lead us
to hypothesize that in addition to undergoing aberrant melano-
cytic transdifferentiation, MDA-MB-435 cells are also capable of
undergoing neuronal/glial-lineage transdifferentiation.
mRNA transcripts of neuronal/glial, epithelial and
melanocytic differentiation markers are co-expressed by
MDA-MB-435 and other breast, melanoma and
glioblastoma cancer cell lines
Subsequently, we determined the expression of epithelial (ESA)
and mammary epithelial (EMA, CK19, CK17) differentiation
markers by RT-PCR analysis. In addition to the ER
2/PR
2/
HER2
2 MDA-MB-435 cells, we also included the ER
+/PR
+
luminal MCF-7 human breast cancer cell line (Figure 2, lane 2),
the ER
2/PR
2/HER2
+ luminal SKBR3 human breast cancer line
(lane 3), and the highly metastatic basal ER
2/PR
2/HER2
2
MDA-MB-231 (lane 4) breast cancer cell line as representatives of
the major clinical subtypes of human breast cancer [14]. The
immortalized MCF-10A cell line derived from normal basal
mammary epithelium was chosen as a non-malignant control for
comparison (Figure 2, lane 1). As expected, both the normal and
malignant mammary epithelial cell lines expressed the epithelial
markers EMA (epithelial membrane antigen, also known as MUC-
1) and ESA (epithelial specific antigen) [Figure 2(I), lanes 1–5].
While MCF-10A cells abundantly express the basal epithelial
marker cytokeratin 17 (CK17) [Figure 2(I), lane 1], CK17 was
weakly expressed by basal metastatic MDA-MB-231 cancer cells
[Figure 2(I), lane 4], and was largely absent in MDA-MB-435
cells [Figure 2(I), lane 5]. However, the basal marker CK17 was
detected in luminal MCF-7 cells [Figure 2(I), lane 2]. In
comparison to CK17 expression, the luminal epithelial differen-
tiation marker cytokeratin 19 (CK19) was expressed at high levels
by luminal MCF-7 and weakly by SKBR3 cells [Figure 2(I),
lanes 2–3]. CK19 was also expressed by MDA-MB-231 cells
[Figure 2(I), lane 4] but was absent in MCF-10A non-malignant
cells and in MDA-MB-435 cancer cells [Figure 2(I), lanes 1
Figure 2. PCR analysis of mRNA expression of neuronal/glial, epithelial and melanocytic differentiation markers in vitro. Expression of
epithelial (I), melanocytic (II) and neuronal/glial markers (III) by MCF-10A normal mammary epithelial cells (lane 1), breast cancer cell lines (lane 2–5),
melanoma (lane 6), and glioblastoma cells (lane 7 and 8). TBP is used as a loading control.
doi:10.1371/journal.pone.0009712.g002
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differentiation markers in cultured and non-induced MDA-MB-
435 cells is consistent with its characterization as a poorly
differentiated cancer cell line [4]. These results demonstrate that
the expression of luminal and basal epithelial differentiation is
aberrant in human breast cancer cell lines.
Thereafter, we determined the expression of three melanocytic
differentiation markers (MITF, melan-A and tyrosinase) in breast
cancer cell lines. We included human melanoma cell line Ul-MeL
as a positive control for this analysis (Figure 2, lanes 6).
Consistent with previous reports [3,6–8], all three melanocytic
markers were expressed by MDA-MB-435 cells [Figure 2(II),
lane 5]. The expression of all or a sub-set of the three markers was
also detected in MCF-7, SKBR3 and normal MCF-10A cells
[Figure 2(II), lanes 1–3]. Weak but detectable expression of
MITF and melan-A was seen in MDA-MB-231 cells, and
tyrosinase (TYR) was nearly absent in MDA-MD-231 cells
[Figure 2(II), lane 4]. As anticipated, Ul-MeL melanoma cells
express all three melanocytic markers [Figure 2(II), lanes 6].
Consistent with observed morphology of neuronal/glial cell
differentiation (Figure 1A, B), two neuronal markers, nestin and
b3-tubulin, were robustly expressed by all four-breast cancer cell
lines including MDA-MB-435 cells [Figure 2(III), lanes 2–5].
In contrast, their mRNA expression was much lower in non-
malignant MCF-10A cells [Figure 2(III), lane 1]. Nestin and
b3-tubulin mRNA transcripts were also detected in the two
metastatic human glioblastoma cell lines U87 and D54
[Figure 2(III), lanes 7–8]. The glial cell marker GFAP mRNA
transcript was only detected in SKBR3 and MDA-MB-231 cells
[Figure 2(III), lanes 3–4]. While we failed to detect GFAP
mRNA expression in cultured MDA-MB-435, U87 and D54 cells
[Figure 2(III), lanes 5, 7–8], we observed abundant specific
GFAP protein expression in these cell lines by immunofluorescent
(IFC) and immunohistochemistry (IHC) analyses (Figure 3).
These observations demonstrate that co-expression of multi-
lineage differentiation markers, including epithelial, melanocytic
and neuron/glial occurs in human breast cancer cell lines. Similar
findings were observed in MDA-MB-435-GFP, MDA-MB-435-
GFP-L cell lines and in MDA-MB-435-GFP cell lines derived from
expansion of a single MDA-MB-435-GFP cell (data not shown).
Thus, expression of melanocytic and neuronal/glial differentiation
markers in our analysis could not be due to contamination of the
MDA-MB-435 culture stock we used in this study with either
melanoma or glioblastoma cancer cells.
To confirm our novel findings on neuronal/glial differentiation
based on RT-PCR analyses, we conducted IFC and IHC analyses
of the protein expression of lineage markers in cultured MDA-MB-
435 cells (Figure 3). Consistent with the lack of cytokeratin mRNA
Figure 3. Determination of protein expression of lineage markers in cultured MDA-MB-435 cells. A, immunofluorescence staining of
epithelial (ESA), melanocytic (melan-A) and neuronal/glial markers (GFAP and nestin) in cultured MDA-MB-435, U87 glioblastoma and Ul-Mel
melanoma cancer cell lines. B, immunohistochemistry staining of lineage markers in embedded MDA-MB-435 cells. AE1/AE3: pan-cytokeratin
epithelial marker.
doi:10.1371/journal.pone.0009712.g003
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to detect pan-cytokeratin protein expression in embedded MDA-
MD-435 cells by IHC staining (Figure 3B). Compared to the Ul-
MeL melanoma cell line that expressed high levels of melan-A
(Figure 3A), the protein expression level of this melanocytic
differentiation marker was considerably lower in MDA-MD-435
and U87 cells (Figure 3A). In contrast, cultured MDA-MB-435
cells strongly expressed both GFAP and nestin proteins. Similar
patterns of IHC staining of GFAP and nestin were observed
(Figure 3). The discrepancy between mRNA and protein
expression of cytokeratin and GFAP could be due to differences
in mRNA stability among genes analyzed. This observation
highlightsthe importanceof using multiple complementary analyses
for drawing conclusions from gene expression assessment.
Further, we also observed aberrant transdifferentiation or
lineage infidelity in the Ul-MeL melanoma cell line that co-
expresses epithelial and neuronal markers [Figure 2(I) (III),
lanes 6], and in two glioblastoma tumor cell lines that co-express
epithelial and melanocytic markers [Figure 2(I) (II), lanes 7–8].
These findings indicate that terminal differentiation to the
anticipated cellular type is altered in the cancerous state and that
the phenomena of lineage infidelity that is associated with the
ability of cancer cells to transdifferentiate, occurs in different
cancer types and is not limited to breast cancer.
Co-expression of multi-lineage protein markers in
MDA-MB-435 primary tumors and metastases
To further confirm that the expression of epithelial, melanocytic
and neuronal/glial markers in MDA-MB-435 cells is not due to an
artifact of cell culture, MDA-MB-435 primary tumors growing
orthotopically in the mammary fat pad (m.f.p) of nude mice and
pleural macro- and micro-metastases of MDA-MB-435 were
utilized for the analyses of the expression of three cellular lineage
markers by IHC (Figure 4 and Methods). We consistently
observed more robust and consistent MDA-MB-435 tumor growth
(higher tumor cell take rate, initiation of tumor growth, higher
level of tumor angiogenesis and higher incidence of lung
metastasis) at the m.f.p, than when MDA-MD-435 was trans-
planted under the skin of the hind leg or on the back. These
observations demonstrate that the m.f.p represents a more
favorable microenvironment for MDA-MB-435 tumor initiation,
expansion and progression, consistent with its ability to undergo
mammary epithelial differentiation [9,14]. While cultured MDA-
MB-435 cells were negative for AE1/AE3 staining for pan-
Figure 4. Determination of protein expression of lineage markers in MDA-MB-435 xenografts and in metastatic lesions.
Immunohistochemical detection of epithelial (AE1/AE3, ESA), melanocytic (melan-A), and neuronal/glial markers (GFAP, nestin) in orthotopic
mammary fat pad tumors, and mammary duct differentiation (H&E) (A), pleural lung macrometastases (B) and lung micrometastases (C, arrows).
doi:10.1371/journal.pone.0009712.g004
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tumors exhibited weakly positive staining for AE1/AE3
(Figure 4A) and strong staining for ESA. This observation is
consistent with a previous report [11]. Additionally, we also
observed evidence of mammary duct differentiation at the
periphery of MDA-MB-435 tumors (Figure 4A, H&E panel).
Similar to IFC, IHC and PCR analyses in vitro, both the orthotopic
primary tumor and macro/micro lung metastases displayed
intense and homogenous expression of nestin and GFAP
(Figure 4). In contrast, strong melan-A staining was only detected
in discrete clusters of cancer cells within the primary tumor
(Figure 4A).
Based on the close clustering of MDA-MB-435 cells with
melanoma cell lines in microarray analysis [5], the possibility of
the breast cancer patient, from whom MDA-MB-435 was derived
from, having an undetected occult melanoma was suggested.
However, cell lines generated from breast tumors and from non-
small lung carcinoma used in the same micro-array study also
failed to yield a clear clustering pattern according to their tissue of
origin. In particular, two other invasive breast cancer cell lines,
Hs578T and BT-549 were clustered together with brain tumor cell
lines, a finding that is consistent with our detection of neuronal
and glial differentiation markers in breast cancer cell lines.
Further, a recent report demonstrated a wide spectrum of
expression of melanocyte-related genes in histologically confirmed
human breast tumor specimens [3]. It thus appears that aberrant
co-expression of multi-lineage markers via transdifferentiation or
lineage infidelity occurs frequently in breast cancer. Therefore,
molecular signatures derived from gene expression profiling should
not be used as exclusive evidence or criteria to determine the tissue
origin of a cancer cell line or a metastatic lesion from an occult
primary tumor. Functional properties such as in vitro functional
characterization of cellular differentiation (acinus formation in 3D
gel culture, production of milk products upon induction of lineage-
specific differentiation), in vivo tumor growth and progression
should all be taken into account when we consider the
classification of a human cancer cell line.
We have demonstrated in this report the co-expression of three
ectoderm cell lineage differentiation markers by a panel of breast
cancer cell lines, by MDA-MB-435 cells obtained from the ATCC,
by cell lines derived from single-cell cloning of MDA-MB-435 and
MDA-MB-435 cells derived from lung metastases grown in vitro;
and as well as by MDA-MB-435 orthotopic primary tumors and
lung metastases in vivo. It is thus highly unlikely that this cell line
was contaminated by both melanoma cells and neuron/glial
cancer cells, or that the breast cancer patient from whom MDA-
MB-435 cells were derived also had an undiagnosed melanoma
and undiagnosed glioblastoma.
In conclusion, our observations indicate that aberrant multi-
lineage transdifferentiation or lineage infidelity occurs frequently
in multiple types of human cancer and may be a wide spread
phenomenon.
Author Contributions
Conceived and designed the experiments: QZ HRX. Performed the
experiments: QZ HF JS. Analyzed the data: QZ HF JS HRX. Contributed
reagents/materials/analysis tools: RH HRX. Wrote the paper: QZ JS RH
HRX.
References
1. Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, et al. (2002) Activation of
different Wnt/beta-catenin signaling components in mammary epithelium
induces transdifferentiation and the formation of pilar tumors. Oncogene 21:
5548–56.
2. Quiro ´s I, Sa ´inz RM, Hevia D, Garcia-Suarez O, Astudillo A, et al. (2009)
Upregulation of manganese superoxide dismutase (SOD2) is a common pathway
for neuroendocrine differentiation in prostate cancer cells. Int J Cancer 125:
1497–604.
3. Montel V, Suzuki M, Galloy C, Mose ES, Tarin D (2009) Expression of
melanocyte-related genes in human breast cancer and its implications.
Differentiation 78: 283–91.
4. Cailleau R, Olive M, Cruciger QV (1978) Long-term human breast carcinoma
cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911–5.
5. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic
variation in gene expression patterns in human cancer cell lines. Nat Genet 24:
227–35.
6. Ellison G, Klinowska T, Westwood RF, Docter E, French T, et al. (2002)
Further evidence to support the melanocytic origin of MDA-MB-435. Mol
Pathol 55: 294–9.
7. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene
amplified in malignant melanoma. Nature 436: 117–122.
8. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-
435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a
boon for melanoma research. Breast Cancer Res Treat 104: 13–9.
9. You H, Yu W, Sanders BG, Kline K (2001) RRR-alpha-tocopheryl succinate
induces MDA-MB 435 and MCF-7 human breast cancer cells to undergo
differentiation. Cell Growth Differ 12: 471–80.
10. Howlett AR, Petersen OW, Steeg PS, Bissell MJ (1994) A novel function for the
nm23-1 gene: overexpression in human breast carcinoma cells leads to the
formation of basement membrane and growth arrest. J Natl Cancer Inst 86:
1838–44.
11. Sellappan S, Grijalva R, Zhou X, Yang W, Bar Eli M, et al. (2004) Lineage
infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast
cancer cell line. Cancer Res 64: 3479–85.
12. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, et al. (2009) Distinct gene
mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res Treat;DOI: 10.1007/s10549-009-0460-8.
13. Li XM, Wang JW, An ZL, Yang M, Baranov E, et al. (2002) Optically
imageable metastatic model of human breast cancer. Clin and Expt Metastasis
19: 347–350.
14. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10: 515–27.
Aberrant Transdifferentiation
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9712